Tech Center 1600 • Art Units: 1623 1642 1646
This examiner grants 48% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 14701912 | RNA-Guided Human Genome Engineering | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 14681510 | RNA-Guided Human Genome Engineering | Non-Final OA | President and Fellows of Harvard College |
| 14318933 | RNA-Guided Human Genome Engineering | Non-Final OA | President and Fellows of Harvard College |
| 19074044 | FORMULATIONS FOR NEOPLASIA VACCINES | Non-Final OA | The Broad Institute, Inc. |
| 16221369 | PURIFICATION OF MULTISPECIFIC ANTIBODIES | Non-Final OA | Genentech, Inc. |
| 17625264 | Methods of Enhancing Immunogenicity of Cancers | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18062937 | PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY | Non-Final OA | The Board of Regents of The University of Texas System |
| 17736535 | Screening and Assessment of Carcinomas | Final Rejection | NEW YORK UNIVERSITY |
| 17625326 | TUMOR IMMUNOTHERAPY USING SINDBIS VIRAL VECTORS AND AGONIST MONOCLONAL ANTIBODIES | Final Rejection | New York University |
| 18351151 | BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME | Final Rejection | The Trustees of the University of Pennsylvania |
| 17089408 | COMPOSITIONS AND METHODS FOR PERSONALIZED NEOPLASIA VACCINES | Non-Final OA | The General Hospital Corporation |
| 16528195 | Compositions and Methods of Identifying Tumor Specific Neoantigens | Final Rejection | The General Hospital Corporation |
| 16094786 | IMPROVED HLA EPITOPE PREDICTION | Non-Final OA | The General Hospital Corporation |
| 18629488 | GENETIC ALTERATIONS IN ISOCITRATE DEHYDROGENASE AND OTHER GENES IN MALIGNANT GLIOMA | Non-Final OA | Duke University |
| 17910637 | A Combined Inhibition of EGFR and NRF2 in The Treatment of Malignant Glioma | Non-Final OA | United States Government as represented by the Department of Veterans Affairs |
| 18161781 | NOVEL BLOOD CELL BIOMARKER FOR LATE ONSET ALZHEIMER'S DISEASE | Non-Final OA | Cedars-Sinai Medical Center |
| 18593621 | CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF | Final Rejection | EUREKA THERAPEUTICS, INC. |
| 17987058 | COMPOSITIONS AND METHODS OF TREATMENT OF SICKLE CELL ANEMIA AND BETA-THALASSEMIA | Non-Final OA | Cleveland State University |
| 16695894 | CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF USE THEREOF | Non-Final OA | Allogene Therapeutics, Inc. |
| 18361407 | GLYPICAN EPITOPES AND USES THEREOF | Final Rejection | MINOMIC INTERNATIONAL LTD. |
| 14296204 | REPEATED ADMINISTRATION OF NON-IMMUNOSUPPRESSIVE ANTIGEN SPECIFIC IMMUNOTHERAPEUTICS | Non-Final OA | Selecta Biosciences, Inc. |
| 17631378 | COMBINED CANCER THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS | Final Rejection | PureTech LYT, Inc. |
| 17634424 | IMMUNE CHECKPOINT INHIBITOR, THERAPEUTIC AGENT FOR IMMUNE CHECKPOINT-RELATED DISEASE, IMMUNOSUPPRESSANT, ANTI-FIBRONECTIN ANTIBODY OR DERIVATIVE THEREOF, FIBRONECTIN ANALOG, KIT FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF, AND METHOD FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF | Final Rejection | Tohoku Techno Arch Co., Ltd. |
| 17616519 | METHODS FOR MODULATING A TREATMENT REGIMEN | Non-Final OA | VERACYTE SAS |
| 16381791 | COMPOSITIONS AND METHODS OF IDENTIFYING TUMOR SPECIFIC NEOANTIGENS | Non-Final OA | Dana Farber Cancer Institute, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy